The ENABLE project has achieved its initial goals to identify three antibacterial leads, select two antibacterial development candidates and advance one compound into Phase I development.
Author Archive for: TG
About Thomas Gabrielczyk
This author has yet to write their bio.Meanwhile lets just say that we are proud Thomas Gabrielczyk contributed a whooping 329 entries.
Entries by Thomas Gabrielczyk
Bionetix, ProQinase, and MercachemSyncom have announced that they will jointly develop a new AML drug, from target identification to clinical testing
Merck KGaAs 2017 Swiss cancer spin-out iOnctura SA has raised 15m to bring its PI3K? inhibitor and autotaxin inhibitor to the clinic.
mRNA cancer neoantigen specialist BioNTech AG is set to buy all shares of Neon Therapeutics, Inc. expanding its pipeline of neoantigen-targeting therapies and getting foothold in the US.
British researchers have identified several small molecule drugs that sensitized B cell cancers to chemotherapy and extended survival in mouse models.
Adaptimmune Therapeutics plc and Japanese Astellas Pharma, Inc. have signed a discovery partnership to develop off-the-shelf allogeneic T cell-based cancer therapies from stem cells.
Twelve years after Roches $6.8bn hostile takeover bid for Illumina, the companies have entered into a 15-year partnership to boost personalised NGS-based cancer testing.
Incyte Corp. has signed a global license agreement for commercialisation of Morphosys AGs anti-CD-19 programme tafasitamab.
In silico clinical trials pioneer Novadiscovery SA has raised 5m in a series A financing led by Swiss Debiopharm Innovation Fund.
Following a 1.5m seed financing in 2017, cancer specialist Alderaan Biotechnology SAS has raised 18.5m in a Series A round led by Advent France Biotechnology and Medicxi.